(Q34893948)

5 August 2017

title

Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood--brain barrier disruption in multiple sclerosis (English)

1 reference

ORCID Public Data File 2021

5 August 2017

0 references

1 reference

author name string

Bibiana Bielekova

1

1 reference

5 August 2017

Nancy Richert

2

1 reference

5 August 2017

Thomas Howard

3

1 reference

5 August 2017

Amy N Packer

4

1 reference

5 August 2017

Gregg Blevins

5

1 reference

5 August 2017

Joan Ohayon

6

1 reference

5 August 2017

Henry F McFarland

7

1 reference

5 August 2017

Claus-Steffen Stürzebecher

8

1 reference

5 August 2017

Roland Martin

9

1 reference

5 August 2017

publication date

23 September 2009

1 reference

Multiple Sclerosis Journal

5 August 2017

published in

1 reference

5 August 2017

volume

15

1 reference

5 August 2017

issue

10

1 reference

5 August 2017

page(s)

1206-1214

1 reference

Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV.

5 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085182

Therapeutic benefit of PDE4 inhibitors in inflammatory diseases.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085182

Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085182

The role of protein kinase A and A-kinase anchoring proteins in modulating T-cell activation: progress and future directions

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085182

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085182

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085182

Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085182

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085182

Rolipram reduces excitotoxic neuronal damage

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085182

Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085182

Differential effects of phosphodiesterase type 4-specific inhibition on human autoreactive myelin-specific T cell clones

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085182

Development of a multiple sclerosis functional composite as a clinical trial outcome measure

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085182

Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085182

Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future?

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085182

Clinical scales for multiple sclerosis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085182

The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085182

Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085182

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085182

Method for quantification of brain, ventricular, and subarachnoid CSF volumes from MR images

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085182

Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis: an additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitors.

8 July 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509345903

Correspondence of closest gradient voxels--a robust registration algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509345903

Relationship between inflammatory lesions and cerebral atrophy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509345903

VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509345903

Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509345903

A pilot study of recombinant insulin-like growth factor-1 in seven multiple sderosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509345903

Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509345903

Amelioration of collagen II-induced arthritis in rats by the type IV phosphodiesterase inhibitor Rolipram

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085182

The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice

26 October 2018

1 reference

12 December 2020

Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram

1 reference

12 December 2020

Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats

1 reference

12 December 2020

Peripheral phosphodiesterase 4 inhibition produced by 4-[2-(3,4-Bis-difluoromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]-3-methylpyridine-1-oxide (L-826,141) prevents experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand

1 reference

12 December 2020

Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats

1 reference

12 December 2020

The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats

1 reference

12 December 2020

Phosphodiesterase type IV inhibitors in the treatment of multiple sclerosis

1 reference

12 December 2020

Differential expression of cyclic nucleotide phosphodiesterase 3 and 4 activities in human T cell clones specific for myelin basic protein

1 reference

12 December 2020

Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease

1 reference

12 December 2020

Identifiers

DOI

10.1177/1352458509345903

1 reference

release_lbvexrnymjb6xj7nl6tt2ahqui

5 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/lbvexrnymjb6xj7nl6tt2ahqui

24 November 2022

mapped directly with Wikidata item

PMC publication ID

3085182

1 reference

5 August 2017

1 reference